Japanese Yen vs Malaysian Ringgit (JPYMYR) Chart

Standard Uranium Vice President of Exploration Sean Hillacre joined Steve Darling from Proactive to provide an update on the company’s geophysical programs across three of its 100%-owned uranium projects in the Eastern Athabasca Basin. These surveys are a key part of Standard Uranium’s targeted exploration strategy, aimed at advancing its portfolio toward high-grade uranium discoveries. The company has reported positive results from high-resolution ground gravity surveys on the Atlantic and Rocas projects and airborne time-domain electromagnetic survey on the Corvo project Hillacre explained that these surveys are helping to refine high-priority exploration targets by providing new geological data layers that highlight lithological variations, potential alteration signatures, and key structural features. The results also improve the understanding of basement conductors, which are closely associated with uranium mineralization in the region. The completion of these surveys marks an important step forward in Standard Uranium’s exploration program. With enhanced geological insights and refined targeting, the company is well-positioned to advance its projects in one of the world’s premier uranium districts. #proactiveinvestors #standarduraniumltd #tsxv #stnd #otcqb #sttdf #mining #uranium #sundogproject #Mining #StandardUranium #Exploration #Geophysics #DrillReady #NuclearEnergy #Investing #MiningStocks #ProactiveInvestors

Immunic Therapeutics Chief Scientific Officer Dr. Hella Kohlhof joined Steve Darling from Proactive to discuss the company’s progress in developing vidofludimus calcium, a novel treatment designed to combat multiple sclerosis (MS) through a unique dual mode of action. The drug offers neuroprotection, anti-inflammatory effects, and antiviral benefits, addressing key aspects of MS pathology. Dr. Kohlhof emphasized the urgent need for therapies that prevent disability progression in MS patients, helping them maintain independence for as long as possible. She explained that vidofludimus calcium achieves this by activating Nurr1 to promote neuroprotection while simultaneously inhibiting DHODH, reducing inflammation and Epstein-Barr virus (EBV) reactivation—both believed to play a role in MS development and progression. A major milestone for Immunic Inc. is approaching, with the phase 2 CALLIPER trial readout expected in April 2025. This study aims to confirm the drug’s neuroprotective effects, positioning it as a potential disease-modifying treatment for MS. Dr. Kohlhof also highlighted vidofludimus calcium’s strong safety and tolerability profile, noting that it is a once-daily oral tablet that requires no treatment monitoring, making it a convenient option for patients. Looking ahead, Immunic is also advancing phase 3 ENSURE trials for relapsing MS, expected to complete in 2026. With limited treatment options for progressive MS, Dr. Kohlhof underscored the high unmet medical need and the potential impact of vidofludimus calcium on improving patient outcomes worldwide. #proactiveinvestors #immunicinc #nasdaq #imux #MSResearch #VidofludimusCalcium #Neuroprotection #ImmunicInc #MSAwareness #CALLIPERTrial #MSBreakthrough #MSDisability #ClinicalTrials

Provaris Energy Ltd (ASX:PV1, OTC:GBBLF) managing director and CEO Martin Carolan talked with Proactive about the company’s latest progress in hydrogen transport and storage solutions. The company has signed a second non-binding memorandum of understanding (MoU) to supply hydrogen from Norway to Germany, aiming for discussions on non-binding term sheets by mid-2025. Carolan emphasised that Provaris is in a "sweet spot" given the industry’s shift towards practical hydrogen projects, with a focus on cost efficiency and scalable delivery. He highlighted that recent developments in Germany reinforce the country’s commitment to hydrogen as a decarbonistion strategy. Additionally, Provaris is advancing its CO2 storage initiative through a joint development with Yinson Production, targeting large-scale liquid CO2 storage solutions. The company also secured the Fiska facility in Norway, which will play a role in testing and validating its H2 Neo carrier technology. Looking ahead, Carolan noted that investors can anticipate key milestones, including binding hydrogen sales agreements and further progress on CO2 storage projects. For more insights from industry leaders, visit Proactive’s YouTube channel, like this video, subscribe, and turn on notifications for future updates. #ProvarisEnergy #Hydrogen #EnergyTransition #Germany #Norway #CO2Storage #RenewableEnergy #SustainableSolutions #HydrogenTransport #GreenEnergy

Delivra Health Brands CEO Gord Davey joined Steve Darling from Proactive to announce the launch of Dream Water 6-Count Sleep Gummies in the Canadian market. This new product builds on the success of the 60-count Dream Water Gummies, which debuted in Canada in February 2024 and received strong consumer demand. The 6-count version is set to hit distributors, retailers, and e-commerce channels in March 2025. Davey highlighted that this strategic launch is aimed at capturing growth opportunities in the travel and convenience retail sectors, reinforcing Delivra Health’s position as a leading provider of sleep solutions. By offering a smaller, on-the-go format, the company aims to expand its reach to travelers and impulse buyers, broadening accessibility for consumers seeking convenient sleep aids. The momentum behind Dream Water Sleep Gummies continues to build in both Canada and the U.S., with the new 6-count format being distributed nationwide through Delivra Health’s established retail and e-commerce partners. With this expansion, the company is set to further strengthen its footprint in the sleep wellness market. #proactiveinveestors #delivrahealthbrandsinc #tsxv #dhb #otcqb #dhbuf #DreamWater #GlobalExpansion #UAE #MiddleEastMarket #SleepAid #HealthAndWellness #PharmacyProducts #RegulatoryCompliance #DreamWater #SleepGummies #Wellness #SleepAid #TravelEssentials #CanadianRetail #HealthAndWellness #InsomniaRelief #SleepBetter